TP53 and neoplasm: Over 50% of human cancers overexpress mutant forms of p53. A growing number of studies suggests that the nature of a p53 mutation in a cell can impact upon cellular properties, clinical responses to therapy and prognosis of a tumour (Canale et al., 2017; Labbé et al., 2017).